Base de dados : MEDLINE
Pesquisa : D03.066.349.570 [Categoria DeCS]
Referências encontradas : 180 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 18 ir para página                         

  1 / 180 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370192
[Au] Autor:Debnath SK; Saisivam S; Debanth M; Omri A
[Ad] Endereço:Department of Pharmacy, Bengal College of Pharmaceutical Sciences and Research, Durgapur, West Bengal, India.
[Ti] Título:Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide.
[So] Source:PLoS One;13(1):e0190976, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prothionamide (PTH), a second line antitubercular drug is used to administer in conventional oral route. However, its unpredictable absorption and frequent administration limit its use. An alternate approach was thought of administering PTH through pulmonary route in a form of nanoparticles, which can sustain the release for several hours in lungs. Chitosan, a bio-degradable polymer was used to coat PTH and further freeze dried to prepare dry powder inhaler (DPI) with aerodynamic particle size of 1.76µm. In vitro release study showed initial burst release followed by sustained release up to 96.91% in 24h. In vitro release further correlated with in vivo study. Prepared DPI maintained the PTH concentration above MIC for more than 12h after single dose administration and increased the PTH residency in the lungs tissue more than 24h. Animal study also revealed the reduction of dose in pulmonary administration, which will improve the management of tuberculosis.
[Mh] Termos MeSH primário: Quitosana/química
Nanopartículas/química
Protionamida/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Tamanho da Partícula
Pós
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Powders); 76YOO33643 (Prothionamide); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190976


  2 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28000029
[Au] Autor:Tan Y; Su B; Zheng H; Wang Y; Pang Y
[Ad] Endereço:Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangdong, Guangzhou, China.
[Ti] Título:Prothionamide susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECMGIT 960 system.
[So] Source:Eur J Clin Microbiol Infect Dis;36(5):779-782, 2017 May.
[Is] ISSN:1435-4373
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Resazurin microtitre assay (RMA) has been successfully used to detect minimal inhibitory concentrations (MICs) of both first-line and several second-line drugs in drug susceptibility testing (DST) of Mycobacterium tuberculosis (MTB). In this study, we firstly compared prothionamide (PTH) susceptibility testing of Mycobacterium tuberculosis (MTB) using resazurin microtitre assay (RMA) and MGIT. Overall, the sensitivity and specificity of RMA for detecting PTH susceptibility was 96.5% [95% confidence interval (CI): 91.7-100.0] and 93.2% (95% CI: 89.6-96.8) respectively. In addition, the median time to positivity was significantly shorter for RMA than for the automated MGIT 960 (RMA, 8 days [range: 8-8 days] vs MGIT, 10.1 days, [range: 5.0-13.0]; P < 0.01). Concordance rate for MICs between RMA and MGIT for PTH-resistant group was 64.3% (95% CI: 46.5-82.0), which was significantly lower than that of PTH-susceptible group (85.9%, 95% CI: 78.8-93.0; P= 0.01). In conclusion, our data demonstrated that RMA can be used as an acceptable alternative for determination of PTH susceptibility with shorter turn-around time. When compared with MGIT 960, RMA method was prone to produce higher MICs for PTH-resistant MTB strains.
[Mh] Termos MeSH primário: Antituberculosos/farmacologia
Automação Laboratorial/métodos
Indicadores e Reagentes/análise
Testes de Sensibilidade Microbiana/métodos
Mycobacterium tuberculosis/efeitos dos fármacos
Oxazinas/análise
Protionamida/farmacologia
Xantenos/análise
[Mh] Termos MeSH secundário: Sensibilidade e Especificidade
Fatores de Tempo
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antitubercular Agents); 0 (Indicators and Reagents); 0 (Oxazines); 0 (Xanthenes); 1FN9YD6968 (resazurin); 76YOO33643 (Prothionamide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1007/s10096-016-2859-6


  3 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27206439
[Au] Autor:Choi JH; Heo NY; Park SH; Park CS; Jo KM; Kim WG; Nam KH
[Ad] Endereço:Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
[Ti] Título:[Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid].
[So] Source:Korean J Gastroenterol;67(5):267-271, 2016 May 25.
[Is] ISSN:2233-6869
[Cp] País de publicação:Korea (South)
[La] Idioma:kor
[Ab] Resumo:Anti-tuberculosis drugs can produce levels of hepatotoxicity ranging from mild elevation of aminotransferase to severe acute hepatitis. A few cases of drug-induced autoimmune hepatitis or the drug reaction with eosinophilia and systemic symptom (DRESS) syndrome by anti-tuberculosis medications have been reported. However, concomitant occurrence of these two disorders has not been reported. Here, we present a case of severe acute hepatitis with DRESS syndrome and autoimmune hepatitis resulting from primary standard anti-tuberculosis drugs. Both conditions were successfully treated with a systemic steroid regimen.
[Mh] Termos MeSH primário: Síndrome de Hipersensibilidade a Medicamentos/etiologia
Etambutol/uso terapêutico
Hepatite Autoimune/diagnóstico
Isoniazida/uso terapêutico
Tuberculose/tratamento farmacológico
[Mh] Termos MeSH secundário: Alanina Transaminase/metabolismo
Antituberculosos/efeitos adversos
Antituberculosos/uso terapêutico
Ciclosserina/uso terapêutico
Quimioterapia Combinada
Eosinofilia/etiologia
Etambutol/efeitos adversos
Feminino
Hepatite Autoimune/etiologia
Hepatite Autoimune/patologia
Seres Humanos
Isoniazida/efeitos adversos
Levofloxacino/uso terapêutico
Fígado/enzimologia
Protionamida/uso terapêutico
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Antitubercular Agents); 6GNT3Y5LMF (Levofloxacin); 76YOO33643 (Prothionamide); 8G167061QZ (Ethambutol); 95IK5KI84Z (Cycloserine); EC 2.6.1.2 (Alanine Transaminase); V83O1VOZ8L (Isoniazid)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170419
[Lr] Data última revisão:
170419
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160522
[St] Status:MEDLINE
[do] DOI:10.4166/kjg.2016.67.5.267


  4 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26586647
[Au] Autor:Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
[Ad] Endereço:Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Department of Paediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Germany. Electronic address: Stephanie.thee@charite.d
[Ti] Título:A review of the use of ethionamide and prothionamide in childhood tuberculosis.
[So] Source:Tuberculosis (Edinb);97:126-36, 2016 Mar.
[Is] ISSN:1873-281X
[Cp] País de publicação:Scotland
[La] Idioma:eng
[Ab] Resumo:Ethionamide (ETH) and prothionamide (PTH), both thioamides, have proven efficacy in clinical studies and form important components for multidrug-resistant tuberculosis treatment regimens and for treatment of tuberculous meningitis in adults and children. ETH and PTH are pro-drugs that, following enzymatic activation by mycobacterial EthA inhibit InhA, a target shared with isoniazid (INH), and subsequently inhibit mycolic acid synthesis of Mycobacterium tuberculosis. Co-resistance to INH and ETH is conferred by mutations in the mycobacterial inhA promoter region; mutations in the ethA gene often underlie ETH and PTH monoresistance. An oral daily dose of ETH or PTH of 15-20 mg/kg with a maximum daily dose of 1000 mg is recommended in children to achieve adult-equivalent serum concentrations shown to be efficacious in adults, although information on optimal pharmacodynamic targets is still lacking. Gastrointestinal disturbances, and hypothyroidism during long-term therapy, are frequent adverse effects observed in adults and children, but are rarely life-threatening and seldom necessitate cessation of ETH therapy. More thorough investigation of the therapeutic effects and toxicity of ETH and PTH is needed in childhood TB while child-friendly formulations are needed to appropriately dose children.
[Mh] Termos MeSH primário: Antituberculosos/administração & dosagem
Etionamida/administração & dosagem
Mycobacterium tuberculosis/efeitos dos fármacos
Protionamida/administração & dosagem
Tuberculose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Fatores Etários
Animais
Antituberculosos/efeitos adversos
Antituberculosos/farmacocinética
Criança
Pré-Escolar
Composição de Medicamentos
Cálculos da Dosagem de Medicamento
Farmacorresistência Bacteriana/genética
Etionamida/efeitos adversos
Etionamida/farmacocinética
Seres Humanos
Lactente
Mycobacterium tuberculosis/genética
Mycobacterium tuberculosis/crescimento & desenvolvimento
Protionamida/efeitos adversos
Protionamida/farmacocinética
Resultado do Tratamento
Tuberculose/diagnóstico
Tuberculose/microbiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antitubercular Agents); 76YOO33643 (Prothionamide); OAY8ORS3CQ (Ethionamide)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151121
[St] Status:MEDLINE


  5 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26219021
[Au] Autor:Yilmaz A; Bolukbasi O
[Ad] Endereço:Istanbul University, Science Faculty, Physics Department, Vezneciler, 34134 Istanbul, Turkey. Electronic address: ayberk@istanbul.edu.tr.
[Ti] Título:Molecular structure and vibrational spectroscopic studies of prothionamide by density functional theory.
[So] Source:Spectrochim Acta A Mol Biomol Spectrosc;152:262-71, 2016 Jan 05.
[Is] ISSN:1873-3557
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Prothionamide (PTH) is the secondary drug used against Mycobacterium tuberculosis bacteria and leprosy. The aim of this work was to investigate the potential energy surface map, anharmonic and harmonic vibrational spectra, NBO analysis and ELF (Electron Localization Function) of the title compound using DFT approach with the B3LYP (Becke, three-parameter, Lee-Yang-Parr) exchange-correlation functional with the 6-31G++(d,p) and the Z3POLX basis sets were employed. In the experimental part of this study, FT-Mid IR, FT-Far IR and FT-Raman spectra of the molecule were recorded in the regions 4000-450cm(-1), 700-30cm(-1) and 4000-100cm(-1) respectively in the solid phase. The comparison between calculated and experimental vibrational spectra (infrared and Raman spectra) and assignments of fundamental vibrational modes were characterized by total energy distribution (TED). Theoretical spectra were seen to be in good agreement with those of the experimental ones.
[Mh] Termos MeSH primário: Antituberculosos/química
Protionamida/química
[Mh] Termos MeSH secundário: Modelos Moleculares
Conformação Molecular
Teoria Quântica
Espectroscopia de Infravermelho com Transformada de Fourier
Análise Espectral Raman
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitubercular Agents); 76YOO33643 (Prothionamide)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151109
[Lr] Data última revisão:
151109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150729
[St] Status:MEDLINE


  6 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26069117
[Au] Autor:Lee SH; Seo KA; Lee YM; Lee HK; Kim JH; Shin C; Ghim JR; Shin JG; Kim DH
[Ad] Endereço:Division of Pulmonary, Sleep, and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
[Ti] Título:Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.
[So] Source:Yonsei Med J;56(4):961-7, 2015 Jul.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Low serum concentrations of drugs used to treat multi-drug resistant tuberculosis (MDR-TB) have occasionally been associated with treatment failure. We determined the frequencies of low serum concentrations of anti-MDR-TB drugs, and assessed the effects of these concentrations on 2-month sputum conversion. MATERIALS AND METHODS: The serum levels of moxifloxacin (MF), prothionamide (PTH), and cycloserine (CS) were determined for 89 serum samples by high-pressure liquid chromatography-tandem mass spectrometry. RESULTS: Low serum concentrations of MF, PTH, and CS below the minimal levels of the normal ranges were 83.3% (20/24), 59.2% (29/49), and 71.2% (47/66), respectively. There were no significant differences between the 2-month sputum conversion group (n=25) and the 2-month sputum non-conversion group (n=4) in median drug concentrations (µg/mL) of MF (1.46 vs. 1.60), PTH (0.91 vs. 0.70), and CS (14.90 vs. 14.90). However, a poor compliance rate was significantly greater in the 2-month sputum non-conversion group (75.0%, 3/4) than in the 2-month sputum conversion group (0%, 0/25) (p=0.001). CONCLUSION: The frequency of low serum concentrations of anti-MDR-TB drugs was substantial and might not affect the 2-month sputum conversion rate. Larger prospective studies with timely sampling are needed to investigate the role of therapeutic drug monitoring in MDR-TB.
[Mh] Termos MeSH primário: Antituberculosos/farmacocinética
Ciclosserina/farmacocinética
Fluoroquinolonas/farmacocinética
Protionamida/farmacocinética
Escarro/microbiologia
Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antituberculosos/sangue
Antituberculosos/uso terapêutico
Cromatografia Líquida de Alta Pressão
Ciclosserina/sangue
Ciclosserina/uso terapêutico
Fluoroquinolonas/sangue
Fluoroquinolonas/uso terapêutico
Seres Humanos
Adesão à Medicação
Meia-Idade
Protionamida/sangue
Protionamida/uso terapêutico
Estudos Retrospectivos
Espectrometria de Massas em Tandem
Tuberculose Resistente a Múltiplos Medicamentos/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitubercular Agents); 0 (Fluoroquinolones); 76YOO33643 (Prothionamide); 95IK5KI84Z (Cycloserine); U188XYD42P (moxifloxacin)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150613
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2015.56.4.961


  7 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:25987620
[Au] Autor:Park SI; Oh J; Jang K; Yoon J; Moon SJ; Park JS; Lee JH; Song J; Jang IJ; Yu KS; Chung JY
[Ad] Endereço:Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
[Ti] Título:Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
[So] Source:Antimicrob Agents Chemother;59(8):4429-35, 2015 Aug.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs would allow for optimal individualized dosage adjustments and improve drug safety and therapeutic outcomes. To evaluate the pharmacokinetic (PK) characteristics of clinically relevant, multidrug treatment regimens and to improve the feasibility of TDM, we conducted an open-label, multiple-dosing study with 16 healthy subjects who were divided into two groups. Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), and prothionamide (250 mg) twice daily and pyrazinamide (1,500 mg) once daily were administered to both groups. Additionally, levofloxacin (750 mg) and streptomycin (1 g) once daily were administered to group 1 and moxifloxacin (400 mg) and kanamycin (1 g) once daily were administered to group 2. Blood samples for PK analysis were collected up to 24 h following the 5 days of drug administration. The PK parameters, including the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve during a dosing interval at steady state (AUCτ), were evaluated. The correlations between the PK parameters and the concentrations at each time point were analyzed. The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter. The results indicated that sampling at 1, 2.5, and 6 h postdosing is needed for TDM when all seven drugs are administered concomitantly. This study indicates that PK characteristics must be considered when prescribing optimal treatments for patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT02128308.).
[Mh] Termos MeSH primário: Antituberculosos/administração & dosagem
Antituberculosos/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Ácido Aminossalicílico/administração & dosagem
Ácido Aminossalicílico/farmacocinética
Área Sob a Curva
Ciclosserina/administração & dosagem
Ciclosserina/farmacocinética
Monitoramento de Medicamentos/métodos
Fluoroquinolonas/administração & dosagem
Fluoroquinolonas/farmacocinética
Voluntários Saudáveis
Seres Humanos
Canamicina/administração & dosagem
Canamicina/farmacocinética
Levofloxacino/administração & dosagem
Levofloxacino/farmacocinética
Masculino
Protionamida/administração & dosagem
Protionamida/farmacocinética
Pirazinamida/administração & dosagem
Pirazinamida/farmacocinética
Estreptomicina/administração & dosagem
Estreptomicina/farmacocinética
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antitubercular Agents); 0 (Fluoroquinolones); 2KNI5N06TI (Pyrazinamide); 59-01-8 (Kanamycin); 5B2658E0N2 (Aminosalicylic Acid); 6GNT3Y5LMF (Levofloxacin); 76YOO33643 (Prothionamide); 95IK5KI84Z (Cycloserine); U188XYD42P (moxifloxacin); Y45QSO73OB (Streptomycin)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:161215
[Lr] Data última revisão:
161215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150520
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.00354-15


  8 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25868018
[Au] Autor:Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
[Ad] Endereço:Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon; Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.
[Ti] Título:High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
[So] Source:Int J Tuberc Lung Dis;19(5):517-24, 2015 May.
[Is] ISSN:1815-7920
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:SETTING: Two specialised multidrug-resistant tuberculosis (MDR-TB) treatment units in Cameroon. OBJECTIVE: To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients. DESIGN: Prospective observational study of MDR-TB patients treated with a standardised 12-month regimen including gatifloxacin, clofazimine, prothionamide, ethambutol and pyrazinamide throughout, supplemented by kanamycin and isoniazid during an intensive phase of a minimum of 4 months. Progress was monitored monthly until treatment completion and twice over one year after treatment cessation. RESULTS: Eighty-seven potentially eligible patients were lost and never treated due to delayed availability of test results. Among the 150/236 eligible and treated patients, 134 (89%) successfully completed treatment, 10 died, 5 were lost, 1 failed and none relapsed. The patients' mean age was 33.7 years (range 17-68), 73 (49%) were females, 120 (80%) had failed on previous treatment, 30 (20%) were human immunodeficiency virus seropositive, 62 (43%) had a body mass index <18.5 kg/m(2) and 41 (27%) had radiographic involvement of five or six of the six lung zones. The most important adverse drug event was hearing impairment, which occurred in 46 of 106 (43%) patients. CONCLUSIONS: These results add further evidence for the usefulness of shorter, standardised regimens among patients without second-line drug resistance.
[Mh] Termos MeSH primário: Antituberculosos/efeitos adversos
Antituberculosos/uso terapêutico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Adesão à Medicação/estatística & dados numéricos
Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Camarões
Clofazimina/uso terapêutico
Estudos de Coortes
Intervalos de Confiança
Países em Desenvolvimento
Relação Dose-Resposta a Droga
Esquema de Medicação
Quimioterapia Combinada
Etambutol/uso terapêutico
Feminino
Fluoroquinolonas/uso terapêutico
Seres Humanos
Isoniazida/uso terapêutico
Canamicina/uso terapêutico
Masculino
Meia-Idade
Razão de Chances
Estudos Prospectivos
Protionamida/uso terapêutico
Pirazinamida/uso terapêutico
Medição de Risco
Fatores de Tempo
Resultado do Tratamento
Tuberculose Resistente a Múltiplos Medicamentos/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitubercular Agents); 0 (Fluoroquinolones); 2KNI5N06TI (Pyrazinamide); 59-01-8 (Kanamycin); 76YOO33643 (Prothionamide); 8G167061QZ (Ethambutol); D959AE5USF (Clofazimine); L4618BD7KJ (gatifloxacin); V83O1VOZ8L (Isoniazid)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:150414
[Lr] Data última revisão:
150414
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150414
[St] Status:MEDLINE
[do] DOI:10.5588/ijtld.14.0535


  9 / 180 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25599413
[Au] Autor:Li N; Liao X; Chen L; Wang J; Liu M; Zhang H
[Ad] Endereço:1Department of Respiratory Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China.
[Ti] Título:Antibiotic Susceptibility Patterns of Mycobacterium tuberculosis Isolates from Guizhou Province of China Against 13 Antituberculosis Drugs.
[So] Source:Microb Drug Resist;21(3):292-6, 2015 Jun.
[Is] ISSN:1931-8448
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A total of 92 Mycobacterium tuberculosis isolates were collected from patients with pulmonary tuberculosis (TB) in the Zunyi region between 2011 and 2012. Collected isolates were used to determine antibiotic susceptibility patterns against 13 anti-TB drugs: 4 first-line and 9 second-line (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, para-aminosalicylic acid, amikacin, capreomycin, kanamycin, and prothionamide) drugs. Results showed that among 57 new cases of TB only 66.7% were susceptible to all four first-line anti-TB drugs and 64.9% were susceptible to fluoroquinolones and second-line injectables; 10.5% of new and 22.9% of previously treated cases were multidrug-resistant TB (MDR-TB); and 1.8% of new and 2.9% of previously treated cases were extensively drug-resistant TB (XDR-TB). In addition, 14.3% of MDR-TB cases (2 out of 14) were XDR-TB, which is higher than the average numbers in China (about 8%) and in the world (9.6%). This study confirms that primary transmission of drug-resistant TB, including MDR/XDR-TB, is a real threat to achieving effective control of drug-resistant TB in the Guizhou Province and indicates the necessity to determine antibiotic susceptibility patterns in patients with TB to improve treatment outcomes.
[Mh] Termos MeSH primário: Antituberculosos/farmacologia
Farmacorresistência Bacteriana Múltipla
Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico
Mycobacterium tuberculosis/efeitos dos fármacos
Tuberculose Pulmonar/tratamento farmacológico
[Mh] Termos MeSH secundário: Aminoglicosídeos/farmacologia
Ácido Aminossalicílico/farmacologia
Capreomicina/farmacologia
China/epidemiologia
Tuberculose Extensivamente Resistente a Medicamentos/epidemiologia
Tuberculose Extensivamente Resistente a Medicamentos/microbiologia
Fluoroquinolonas/farmacologia
Seres Humanos
Incidência
Testes de Sensibilidade Microbiana
Mycobacterium tuberculosis/isolamento & purificação
Protionamida/farmacologia
Tuberculose Pulmonar/epidemiologia
Tuberculose Pulmonar/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Antitubercular Agents); 0 (Fluoroquinolones); 11003-38-6 (Capreomycin); 5B2658E0N2 (Aminosalicylic Acid); 76YOO33643 (Prothionamide)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150529
[Lr] Data última revisão:
150529
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150120
[St] Status:MEDLINE
[do] DOI:10.1089/mdr.2014.0094


  10 / 180 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25199531
[Au] Autor:Nunn AJ; Rusen ID; Van Deun A; Torrea G; Phillips PP; Chiang CY; Squire SB; Madan J; Meredith SK
[Ad] Endereço:Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, Aviation House, 125 Kingsway, London WC2B 6NH, UK. andrew.nunn@ucl.ac.uk.
[Ti] Título:Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
[So] Source:Trials;15:353, 2014 Sep 09.
[Is] ISSN:1745-6215
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection. METHODS/DESIGN: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites. DISCUSSION: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB. TRIAL REGISTRATION: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.
[Mh] Termos MeSH primário: Antituberculosos/administração & dosagem
Projetos de Pesquisa
Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico
Tuberculose Pulmonar/tratamento farmacológico
[Mh] Termos MeSH secundário: Bangladesh
Protocolos Clínicos
Clofazimina/administração & dosagem
Esquema de Medicação
Quimioterapia Combinada
Etambutol/administração & dosagem
Fluoroquinolonas/administração & dosagem
Seres Humanos
Isoniazida/administração & dosagem
Canamicina/administração & dosagem
Protionamida/administração & dosagem
Pirazinamida/administração & dosagem
Fatores de Tempo
Resultado do Tratamento
Tuberculose Resistente a Múltiplos Medicamentos/diagnóstico
Tuberculose Resistente a Múltiplos Medicamentos/microbiologia
Tuberculose Pulmonar/diagnóstico
Tuberculose Pulmonar/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitubercular Agents); 0 (Fluoroquinolones); 2KNI5N06TI (Pyrazinamide); 59-01-8 (Kanamycin); 76YOO33643 (Prothionamide); 8G167061QZ (Ethambutol); D959AE5USF (Clofazimine); U188XYD42P (moxifloxacin); V83O1VOZ8L (Isoniazid)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140910
[St] Status:MEDLINE
[do] DOI:10.1186/1745-6215-15-353



página 1 de 18 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde